首页|精准医疗临床研究的关键挑战与优化建议

精准医疗临床研究的关键挑战与优化建议

扫码查看
近年来,随着现代生物技术的成熟,在国际社会共同推动下,致力于为患者提供个性化医疗服务的精准医疗及其相关临床研究取得了显著进展.为促进精准医疗研究及其发展环境的优化,欧盟委员会设立了国际精准医疗联盟(ICPerMed),以专项研究的形式支持精准医疗健康发展.ICPerMed于2020年启动PERMIT专项,该专项致力于推动精准医疗临床研究的发展.本研究围绕PERMIT专项的概况、研究目标、工作内容及其针对精准医疗临床研究发展的相关工作建议等几个方面进行系统介绍;同时结合我国精准医疗临床研究的进展与挑战,提出促进精准医疗临床研究健康高效发展的若干关键工作方向,包括政策制定、监管框架和资金投入等,以供相关工作参考.
Key Challenges and Optimization Recommendations of Clinical Research for Personalised Medicine
In recent years,with the maturity of modern biological technology and the joint promotion of the international community,personalised medicine and its clinical research,which is dedicated to providing personalized medical services to patients,have made sig-nificant progress.In order to promote personalised medicine research and optimize its ecological environment,the European Commission established the International Consortium of Personalised Medicine(ICPerMed)to support the healthy development of personalised medi-cine in the form of project research.ICPerMed set the PERMIT project in 2020,which is dedicated to promoting the development of clini-cal research for personalised medicine.This study systematically introduces the overview,research goals,work content of PERMIT,and its related work suggestions for the development of clinical research for personalised medicine.At the same time,combined with the prog-ress and challenges of clinical research for personalised medicine in China,this study proposes several key work directions to promote healthy and efficient development of clinical research for personalised medicine,including policy formulation,regulatory framework and financial investment,so as to provide reference for related work.

Personalised medicineClinical researchICPerMedPERMIT projectPrecision oncology

杜静婷、冷烨、祁婉婷、韩洞明、王丽丽、黄慧瑶、王闻雅、李宁

展开 >

国家癌症中心,中国医学科学院肿瘤医院,北京 100021

清华大学附属北京清华长庚医院,北京 102218

深圳华大生命科学研究院,广东 深圳 518083

中国科学院大学生命科学学院,北京 100049

展开 >

精准医疗 临床研究 ICPerMed PERMIT项目 肿瘤精准治疗

国家重点研发计划重点专项中国-欧盟国际精准医疗领域合作支持计划(IC2PerMed)

[2021YFE0192400

2024

中国医药导刊
国家食品药品监督管理局信息中心

中国医药导刊

影响因子:1.408
ISSN:1009-0959
年,卷(期):2024.26(1)
  • 20